Azcuris
Latest round
- Series B
Last raised
- Apr 2026
Total raised
- $3.4M
Investors
- 4
About Azcuris
Founded in 2018 and headquartered in Sejong, South Korea, Azcuris specializes in drug discovery for immune-related conditions. Azcuris specializes in the development of innovative small-molecule therapeutics aimed at modulating cytokine signaling pathways to prevent and treat immune diseases. Their primary offering revolves around a proprietary drug discovery platform that focuses on small-molecule immune therapeutics. This platform is designed to control the early stages of immune responses, effectively blocking disease progression. Azcuris targets various immune-related conditions and aims to provide solutions for patients suffering from chronic inflammatory diseases and autoimmune disorders.Azcuris generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations, focusing on the commercialization of their drug discovery platform. Typically, transactions involve licensing agreements where clients pay for access to Azcuris's proprietary technologies or collaborative agreements that may include milestone payments based on research outcomes. The company may also engage in joint ventures with larger firms to facilitate the development and distribution of their therapeutic products. While specific pricing plans for their services are not disclosed, revenue is driven by these collaborations, which align with their mission to innovate in the field of immunotherapy. The flagship offerings, centered around cytokine modulation, position Azcuris to capitalize on the growing demand for specialized immune therapeutics in the market. The company plans to expand its reach into European markets by the end of 2023, capitalizing on the increasing demand for advanced immunotherapies.
Who invested in Azcuris
4 investors across 1 round
See all investors in Azcuris
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Apr 30, 2026
Amount
$3.4M
Investors
Questions about Azcuris
Who invested in Azcuris?
Azcuris has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Azcuris raised?
Azcuris has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Azcuris last raise money?
Azcuris's most recent round on record is a Series B, in Apr 2026.
What does Azcuris do?
Founded in 2018 and headquartered in Sejong, South Korea, Azcuris specializes in drug discovery for immune-related conditions.
Where is Azcuris headquartered?
Azcuris is headquartered in Sejong, South Korea.
Which VCs invest in companies like Azcuris?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Azcuris's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Azcuris? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.